GlaxoSmithKline has announced the purchase of 306,478 of its own ordinary shares as part of its ongoing buyback programme. This transaction, executed through Merrill Lynch International, is part of a ...

GSK Egypt posted non-consolidated net profits after tax of EGP 71.33 million in H1-25, an annual drop from EGP 99.54 million. Meanwhile, the EPS declined to EGP 0.85 from EGP 1.19. In April-June 2025, ...

Arab Finance: GlaxoSmithKline Egypt (GSK–Egypt) logged consolidated net profits for controlling interest of EGP 65.060 ...

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its current portfolio. While the company’s total sales in this period totalled £8bn ...

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK plc announced the acquisition of ordinary shares by several key executives under the ...

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline today and set a price target of £13.97. The company’s shares opened today at p1,424.50. Take advantage of TipRanks Premium ...

Hengrui Pharma partners with GSK to develop 12 innovative medicines, boosting globalization for Hengrui and expanding GSK's oncology and RI&I pipeline.

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on GlaxoSmithKline. The company’s shares closed yesterday at $37.67. Take advantage of TipRanks Premium at 50% off!

Jiangsu Hengrui Pharmaceuticals' shares surged 10% to a 4-year high after licensing HRS-9821 and 11 programs to GlaxoSmithKline. GSK will pay $500 million upfront, with potential milestones reaching ...

GlaxoSmithKline Pharmaceuticals to launch oncology assets Jemperli and Zejula in India, addressing critical unmet needs in ...